UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema
UNITY Biotechnology 宣佈延長評估糖尿病黃斑水腫患者的 UBX1325 ASPIRE 2b 期臨床研究
UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema
UNITY Biotechnology 宣佈延長評估糖尿病黃斑水腫患者的 UBX1325 ASPIRE 2b 期臨床研究
使用瀏覽器的分享功能,分享給你的好友吧